{"id":1604,"date":"2026-06-26T19:45:00","date_gmt":"2026-06-26T19:45:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/"},"modified":"2026-06-28T15:59:36","modified_gmt":"2026-06-28T15:59:36","slug":"backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/","title":{"rendered":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<div class=\"td-post-featured-image\">\n<figure><img decoding=\"async\" width=\"696\" height=\"574\" class=\"entry-thumb td-modal-image\" src=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130-696x574.jpg\" srcset=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130-696x574.jpg 696w, https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130-1392x1148.jpg 1392w\" sizes=\"(-webkit-min-device-pixel-ratio: 2) 1392px, (min-resolution: 192dpi) 1392px, 696px\" alt=\"Inflammatory bowel disease, illustration\" title=\"Getty: 1148113949\"\/><figcaption class=\"wp-caption-text\">Inflammatory bowel illness (illustration). [Christoph Burgstedt\/Science Photo Library\/Getty Images]<\/figcaption><\/figure>\n<\/div>\n<p><span style=\"font-weight: 400;\">Although he&#8217;s educated as a gastroenterologist and scientist, Fr\u00e9d\u00e9ric Marrache, MD, PhD, has all the time had one thing of an entrepreneurial itch. Following his post-doctoral program and a stint in administration consulting, he made his technique to Sanofi the place he would work on early- to mid-stage drug improvement applications targeted on immune-mediated illnesses. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cThis was proper across the time when Sanofi, along with Regeneron, was finalizing the event of Dupixent,\u201d a prescription biologic injection used to deal with a number of inflammatory circumstances, he informed <\/span><span style=\"font-weight: 400;\">GEN<\/span><span style=\"font-weight: 400;\">. These experiences gave him \u201csignificant insights\u201d into affected person care in addition to about \u201chow one can develop therapies on this house.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A kind of insights was the size of the unmet medical want within the immune-driven inflammatory illness house. Although some massive pharma corporations have developed merchandise for the house already, \u201cI had a couple of insights about what could possibly be differentiated,\u201d he mentioned. That led him to interact with a group at Sofinnova Companions in early 2025. \u201cI got here in with my insights about affected person wants, immunology, and goal choice, and [my] view on proper and fallacious property,\u201d he mentioned. \u201cThey got here with expertise in constructing corporations\u201d and \u201cwe mapped out your entire asset house particularly on the goal and pathway of curiosity.\u201d\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">These discussions led to the launch of Bionyra Pharma, a clinical-stage biopharmaceutical firm that&#8217;s growing next-generation biologics for extreme immunological and inflammatory illnesses. The corporate emerged from stealth this week after elevating $165 million in an oversubscribed Collection A. The spherical was co-led by Jeito Capital and Sofinnova Companions with participation from Arkin Bio, Sanofi Ventures, Sixty Diploma Capital, Vives Companions and Apollo Well being Ventures.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Marrache serves because the co-founder and CEO of the corporate. Along with the financing, Mehdi Ainouche, companion at Jeito Capital; Anta Gkelou, companion at Sofinnova Companions; Avital Adler, principal at Arkin Bio; and Laia Crespo, companion at Sanofi Ventures, will be part of Bionyra\u2019s board of administrators.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cAfter we co-founded Bionyra with Fr\u00e9d\u00e9ric, our conviction in each the corporate and his management was grounded in his deep experience in immune and inflammatory illnesses,\u201d mentioned Sofinnova\u2019s Gkelou. \u201cTrying forward, we&#8217;re targeted on advancing these applications with the intention of bringing significant new remedy choices to sufferers.\u201d\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Particularly, the funds will assist Bionyra\u2019s efforts to advance mono and multispecific antibodies for numerous inflammatory circumstances together with atopic dermatitis and inflammatory bowel illness (IBD).\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Proper out of the gate, Bionyra is launching a pipeline of three scientific and near-clinical anti-inflammatory therapies, a few of that are already in scientific trials. The corporate\u2019s first asset, BYN-002 is a TL1A monoclonal antibody with the potential to deal with IBD and different TL1A-relevant indications. This remedy is at the moment in a fully-enrolled Part I research in wholesome folks. Its subsequent candidate, BYN-003, is a TL1A*IL-23p19 bispecific antibody that can be in Part I testing. Each property have been improved with half-life extension (HLE) engineering to maximise efficacy and affected person profit.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Typically talking, \u201cTL1A is a sport changer goal proper now in [immunology and inflammation] with nice ends in inflammatory illness,\u201d he mentioned. Nonetheless, it&#8217;s seemingly that this goal will likely be related throughout a number of indications. To that finish, Bionyra is protecting its choices open when it comes to what it would goal with its TL1A property. \u201cWhether or not it\u2019s going to be within the inflammatory bowel illness house, whether or not we go for one more indication house or whether or not we determine to develop it together in any of those indications, that\u2019s an possibility,\u201d he mentioned.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For now, the main target is on validating the protection and efficacy of each therapies in wholesome volunteers. \u201cThat\u2019s particularly a query across the bispecific antibody\u201d as a result of there&#8217;ll seemingly be questions across the immunogenicity, he famous. \u201cOur benefit right here is that our bispecific is constructed on the spine of our monospecific, so no less than now we have some degree of early validation right here, and we hope to current some outcomes quickly.\u201d\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A 3rd candidate, BYN-001, is an IL-25 monoclonal antibody that has additionally benefited from HLE know-how. It&#8217;s at the moment within the IND-stage for atopic dermatitis and kind 2 irritation. Whereas there are a number of property in improvement that intention to focus on sort 2 irritation, as soon as the entire me-too medication are excluded, the sector turns into narrower, Marrache mentioned whereas explaining the rationale for selecting this specific drug candidate for Bionyra\u2019s portfolio. \u201cIL-25 has been identified to be a robust driver of sort 2 irritation for a while,\u201d he mentioned. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Moreover, some just lately printed early scientific knowledge from a competitor, who&#8217;re growing their very own asset for IL-25, \u201cclearly validated the pathway and prompt potential for differentiation.\u201d On the time, Bionyra was already exploring the identical goal house so \u201cwe had been in a position to transfer in a short time\u201d and discover what, Marrache believes, is the \u201cmost potent IL-25 antibody on the market\u201d with the \u201clongest half life.\u201d\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Two of the property BYN-002 and BYN-003 had been licensed from TrueLab Biopharmaceutical. Below the phrases of the settlement Bionyra was granted unique worldwide rights, excluding Better China, to analysis, develop, manufacture and commercialize each therapies. TrueLab is eligible to obtain as much as $985 million in complete consideration associated to each property, together with the upfront cost in addition to improvement, regulatory, and industrial milestone funds. The settlement additionally contains tiered royalties on future internet gross sales. As well as, TrueLab has a single-digit fairness stake in Bionyra Pharma following completion of its Collection A financing.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For its half, BYN-001 was licensed from NovaRock Biotherapeutics. Bionyra can be progressing further preclinical property together with some from TrueLab. It&#8217;ll assist these efforts with among the funds from the Collection A.<\/span><\/p>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.genengnews.com\/topics\/drug-discovery\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inflammatory bowel illness (illustration). [Christoph Burgstedt\/Science Photo Library\/Getty Images] Although he&#8217;s educated as a gastroenterologist and scientist, Fr\u00e9d\u00e9ric Marrache, MD, PhD, has all the time had one thing of an entrepreneurial itch. Following his post-doctoral program and a stint in administration consulting, he made his technique to Sanofi the place he would work on early- [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1606,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[2059,2063,2058,2066,2060,2065,2064,2062,2061],"class_list":["post-1604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-165m","tag-advance","tag-backed","tag-biologics","tag-bionyra","tag-disease","tag-inflammatory","tag-launches","tag-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24<\/title>\n<meta name=\"description\" content=\"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24\" \/>\n<meta property=\"og:description\" content=\"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-26T19:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-28T15:59:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics\",\"datePublished\":\"2026-06-26T19:45:00+00:00\",\"dateModified\":\"2026-06-28T15:59:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/\"},\"wordCount\":1019,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/GettyImages-1148113949-scaled-e1628770560130.jpg\",\"keywords\":[\"165M\",\"Advance\",\"Backed\",\"Biologics\",\"Bionyra\",\"Disease\",\"Inflammatory\",\"Launches\",\"Pharma\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/\",\"name\":\"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/GettyImages-1148113949-scaled-e1628770560130.jpg\",\"datePublished\":\"2026-06-26T19:45:00+00:00\",\"dateModified\":\"2026-06-28T15:59:36+00:00\",\"description\":\"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/GettyImages-1148113949-scaled-e1628770560130.jpg\",\"contentUrl\":\"https:\\\/\\\/www.genengnews.com\\\/wp-content\\\/uploads\\\/2021\\\/08\\\/GettyImages-1148113949-scaled-e1628770560130.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/06\\\/26\\\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24","description":"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/","og_locale":"en_US","og_type":"article","og_title":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24","og_description":"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/","og_site_name":"Future News 24","article_published_time":"2026-06-26T19:45:00+00:00","article_modified_time":"2026-06-28T15:59:36+00:00","og_image":[{"url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics","datePublished":"2026-06-26T19:45:00+00:00","dateModified":"2026-06-28T15:59:36+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/"},"wordCount":1019,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","keywords":["165M","Advance","Backed","Biologics","Bionyra","Disease","Inflammatory","Launches","Pharma"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/","name":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","datePublished":"2026-06-26T19:45:00+00:00","dateModified":"2026-06-28T15:59:36+00:00","description":"The pipeline includes clinical and IND stage mono and multispecific antibodies that target immune-mediated inflammatory diseases.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#primaryimage","url":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg","contentUrl":"https:\/\/www.genengnews.com\/wp-content\/uploads\/2021\/08\/GettyImages-1148113949-scaled-e1628770560130.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/06\/26\/backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Illness Biologics"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=1604"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1604\/revisions"}],"predecessor-version":[{"id":1605,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1604\/revisions\/1605"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/1606"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=1604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=1604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=1604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}